Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Novoheart Holdings Inc. (V:NVH)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for NVH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

May 19, 2020 06:00 ET
Novoheart Holdings Inc. Reports First Quarter 2020 Financial Results and Announces AGM Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended March 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial...
Read full article
Mar 11, 2020 18:00 ET
Novoheart Holdings Inc. Reports Second Quarter and Fiscal 2019 Financial Results
Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended December 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
241.05
11.96
8.18
Price to Book - most recent quarter
3.13
6.67
2.53
Price to Cash Flow per share - TTM
--
2.60
11.10
Price to Free Cash Flow per share - TTM
--
8.78
22.75
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 202048,80048,729
May 31, 2020710
May 15, 202071-319
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Novoheart Holdings Inc is a Canada-based holding company. The Company, through its subsidiary, provides, discovers and develops heart therapeutics. Novoheart's scientific team has pioneered a range of bioengineering technologies collectively known as the MyHeart platform, including first human mini-heart "novoHeart" that is capable of fully capable of pumping and ejecting fluid. It is currently partnering with a pharmaceutical company to develop human heart tissues and chambers that carry a hereditary neurodegenerative disease. It is anticipated that the pharmaceutical company will be able to use the developed pathological tissues as a unique drug discovery and drug screening platform for effective therapies targeting the heart-associated issues of this specific disease. Novoheart is currently completing the build out a large commercial laboratory in Asia to enable it to service additional potential commercial partnerships, which are under discussion.

See business summary

 

Twitter

Search (past week) for $NVH.CA NVH.V

  • No tweets found